Published

Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada.

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: PloS one
Date: 2024-01-01
Source: PubMed
DOI: 10.1371/journal.pone.0309911
PubMed: 39446753

Authors

Kim K Yusuf A Sud A Persaud N Kirubarajan A Moller M Lloyd T O'Neill B

Watch author

Derived topics and classifications

psilocybin Depression Healthcare Workers Safety Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Critical appraisal of evidence supporting prescription of psychedelics from clinic websites in Ontario, Canada.2024-01-01

Related papers

Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: A randomized controlled trial.PLoS medicine · 2025-09-01 Psychedelic-assisted therapy: An overview for the internist.Cleveland Clinic journal of medicine · 2025-03-03 Psilocybin-Assisted Therapy in Psychiatry: A Narrative Clinical Review of Mechanisms, Therapeutic Applications, and Emerging Evidence (2025-2026)Journal of Clinical Medicine · 2026-08-12 Implementing psilocybin-assisted therapy in palliative care settings: A survey of stakeholdersPalliative Medicine · 2026-07-01 Short-Term and Late-Term Effects of Psilocybin on Symptoms in Major DepressionJAMA Network Open · 2026-05-15 Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept StudyClinicalTrials.gov · 2026-03-11 Group Retreat Psilocybin Therapy for People with Metastatic Cancer with Anxiety and Depression: A Rite of Passage Facilitation Model for a Phase 1/2 Study.Psychedelic medicine (New Rochelle, N.Y.) · 2026-09-01 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant DepressionClinicalTrials.gov · 2026-08-10